EUVIMEDEUVIMED entdecken
Crossref

Hepatocyte Growth Factor and Lung Fibrosis

Bruno Crestani, Sylvain Marchand-Adam, Christophe Quesnel, Laurent Plantier, Keren Borensztajn, Joelle Marchal, Arnaud Mailleux, Paul Soler, Monique Dehoux

Proceedings of the American Thoracic Society · 15.07.2012 · 9 (3) · 158-163

DOI: 10.1513/pats.201202-018aw ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the American Thoracic Society, online erschienen am 15.07.2012. Verfasst von Bruno Crestani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pneumologie A, Hôpital Bichat, 46 rue Henri Huchard, Paris CEDEX 18, France. bruno.crestani@bch.aphp.fr. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 89 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis is currently believed to be driven by alveolar epithelial cells, with abnormally activated alveolar epithelial cells accumulating in an attempt to repair injured alveolar epithelium (1). Thus, targeting the alveolar epithelium to prevent or inhibit the development of pulmonary fibrosis might be an interesting therapeutic option in this disease. Hepatocyte growth factor (HGF) is a growth factor for epithelial and endothelial cells, which is secreted by different cell types, especially fibroblasts and neutrophils. HGF has mitogenic, motogenic, and morphogenic properties and exerts an antiapoptotic action on epithelial and endothelial cells. HGF has also proangiogenic effect. In vitro, HGF inhibits epithelial-to-mesenchymal cell transition and promotes myofibroblast apoptosis. In vivo, HGF has antifibrotic properties demonstrated in experimental models of lung, kidney, heart, skin, and liver fibrosis. Hence, the modulation of HGF may be an attractive target for the treatment of lung fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApoptosisCell SurvivalEndothelial CellsEpithelial CellsEpithelial-Mesenchymal TransitionFibroblastsHepatocyte Growth FactorHumansIdiopathic Pulmonary FibrosisPulmonary AlveoliTransforming Growth Factor betaWound Healing

Substanzen

Transforming Growth Factor betaHepatocyte Growth Factor

Autor:innen und Institutionen

  • Service de Pneumologie A, Hôpital Bichat, 46 rue Henri Huchard, Paris CEDEX 18, France. bruno.crestani@bch.aphp.fr

Zitieren

APA

Crestani, B., Marchand-Adam, S., Quesnel, C., Plantier, L., Borensztajn, K., Marchal, J., Mailleux, A., Soler, P., & Dehoux, M. (2012). Hepatocyte Growth Factor and Lung Fibrosis. Proceedings of the American Thoracic Society, 9(3), 158-163. https://doi.org/10.1513/pats.201202-018aw

Vancouver

Crestani B, Marchand-Adam S, Quesnel C, Plantier L, Borensztajn K, Marchal J, et al. Hepatocyte Growth Factor and Lung Fibrosis. Proceedings of the American Thoracic Society. 2012;9(3):158-163. doi:10.1513/pats.201202-018aw

BibTeX
@article{Crestani2012,
  author = {Crestani, Bruno and Marchand-Adam, Sylvain and Quesnel, Christophe and Plantier, Laurent and Borensztajn, Keren and Marchal, Joelle and Mailleux, Arnaud and Soler, Paul and Dehoux, Monique},
  title = {Hepatocyte Growth Factor and Lung Fibrosis},
  journal = {Proceedings of the American Thoracic Society},
  year = {2012},
  volume = {9},
  number = {3},
  pages = {158--163},
  doi = {10.1513/pats.201202-018aw}
}
Kostenlos starten →